ImmunityBio (IBRX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.22
- Estimate
- -$0.08
- Surprise
- -175.0%
- Revenue (period 2026-06-30)
- $51.2M
- Score at report (before → after)
- 6.2 → 6.2/10
Revenue source: xbrl.
How the report landed
ImmunityBio (IBRX) reported a wider loss than forecast — adjusted EPS of -$0.22 against the -$0.08 estimate (a 175.0% shortfall). TrendMatrix's engine moved from Sell (6.2/10) to Hold at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates IBRX Hold at 6.4/10.
2 of the last 4 quarters beat the estimate; this quarter's -175.0% surprise compares with a -31.8% four-quarter average. Next scheduled report: 2026-11-03.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong growth profile
What argues against it
- Thin upside margin: 9.4%
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.1)
- Elevated risk factors
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $9.91
- Price target
- $10.84
- Stop
- $9.22
- Upside to target
- +9.4%
- Reward-to-risk
- 0.6:1
Risk check: trading volume is running 1.9× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-15 — shown for context, not personalized investment advice.
IBRX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $10.39B
- P/E (fwd)
- -70.0
- 52-week range
- $1.95–$12.43
- Off 52-week high
- 20.3%
- RSI (14)
- 63
- Volume vs avg
- 1.91×
- Score today
- 6.4/10